Cargando…

Salbutamol use in relation to maintenance bronchodilator efficacy in COPD: a prospective subgroup analysis of the EMAX trial

BACKGROUND: Short-acting β(2)-agonist (SABA) bronchodilators help alleviate symptoms in chronic obstructive pulmonary disease (COPD) and may be a useful marker of symptom severity. This analysis investigated whether SABA use impacts treatment differences between maintenance dual- and mono-bronchodil...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maltais, F., Naya, I. P., Vogelmeier, C. F., Boucot, I. H., Jones, P. W., Bjermer, L., Tombs, L., Compton, C., Lipson, D. A., Kerwin, E. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7579818/ https://www.ncbi.nlm.nih.gov/pubmed/33092591 http://dx.doi.org/10.1186/s12931-020-01451-8

Ejemplares similares

Dual Bronchodilator Therapy as First-Line Treatment in Maintenance-Naïve Patients with Symptomatic COPD: A Pre-Specified Analysis of the EMAX Trial
por: Bjermer, Leif, et al.
Publicado: (2021)

Impact of baseline COPD symptom severity on the benefit from dual versus mono-bronchodilators: an analysis of the EMAX randomised controlled trial
por: Vogelmeier, Claus F., et al.
Publicado: (2020)

Efficacy and Safety of Umeclidinium/Vilanterol in Current and Former Smokers with COPD: A Prespecified Analysis of The EMAX Trial
por: Bjermer, Leif H., et al.
Publicado: (2021)

Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial
por: Maltais, François, et al.
Publicado: (2019)

Early and sustained symptom improvement with umeclidinium/vilanterol versus monotherapy in COPD: a post hoc analysis of the EMAX randomised controlled trial
por: Kerwin, Edward M, et al.
Publicado: (2020)

Treatment of COPD with Long-Acting Bronchodilators: Association Between Early and Longer-Term Clinically Important Improvement
por: Vogelmeier, Claus F, et al.
Publicado: (2021)

Efficacy of umeclidinium/vilanterol according to the degree of reversibility of airflow limitation at screening: a post hoc analysis of the EMAX trial
por: Vogelmeier, Claus F., et al.
Publicado: (2021)

Impact of prior and concurrent medication on exacerbation risk with long-acting bronchodilators in chronic obstructive pulmonary disease: a post hoc analysis
por: Naya, Ian, et al.
Publicado: (2019)

Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model
por: Shukla, Soham, et al.
Publicado: (2021)

Future concepts in bronchodilation for COPD: dual- versus monotherapy
por: Singh, Dave, et al.
Publicado: (2021)

Efficacy of Umeclidinium/Vilanterol in Elderly Patients with COPD: A Pooled Analysis of Randomized Controlled Trials
por: Ray, Riju, et al.
Publicado: (2018)

Umeclidinium/Vilanterol Versus Tiotropium/Olodaterol in Maintenance-Naïve Patients with Moderate Symptomatic Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis
por: Alcázar Navarrete, Bernardino, et al.
Publicado: (2018)

Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β(2)-Agonist Therapy: An Integrated Post Hoc Analysis
por: Naya, Ian P., et al.
Publicado: (2018)

Bronchodilator reversibility testing in morbidly obese non-smokers: fluticasone/salmeterol efficacy versus salbutamol bronchodilator
por: Ahmed, Mona Ibrahim, et al.
Publicado: (2023)

An Evaluation Of Single And Dual Long-Acting Bronchodilator Therapy As Effective Interventions In Maintenance Therapy-Naïve Patients With COPD
por: Singh, Dave, et al.
Publicado: (2019)

Bronchodilator response after two methods of salbutamol nebulization in asthmatic children
por: Emeryk, Andrzej, et al.
Publicado: (2022)

Comparative effectiveness of triple therapy versus dual bronchodilation in COPD
por: Voorham, Jaco, et al.
Publicado: (2019)

Bronchodilator response of advanced lung function parameters depending on COPD severity
por: Jarenbäck, Linnea, et al.
Publicado: (2016)

Dual bronchodilation vs triple therapy in the “real-life” COPD DACCORD study
por: Buhl, Roland, et al.
Publicado: (2018)

Small airway bronchodilator response to different doses of salbutamol in 7-year-old children
por: Yon, Dong Keon, et al.
Publicado: (2017)

Which bronchodilator in COPD?
por: Russell, Richard, et al.
Publicado: (2007)

COPD: maximization of bronchodilation
por: Nardini, Stefano, et al.
Publicado: (2014)

Therapeutic Success in Swiss COPD Patients Receiving Dual Bronchodilation Therapy as COPD Maintenance Treatment
por: Spielmanns, Marc, et al.
Publicado: (2022)

Impact of switching from triple therapy to dual bronchodilation in COPD: the DACCORD ‘real world’ study
por: Vogelmeier, Claus F., et al.
Publicado: (2022)

Long-term outcomes following first short-term clinically important deterioration in COPD
por: Naya, Ian P., et al.
Publicado: (2018)

Bronchodilators use in patients with COPD
por: Dong, Yaa-Hui, et al.
Publicado: (2015)

Effects of salbutamol on airway characteristics in mechanically ventilated adults without COPD
por: Van Rosmalen, J, et al.
Publicado: (2012)

Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium
por: Vogelmeier, Claus, et al.
Publicado: (2010)

Optimizing bronchodilation in the prevention of COPD exacerbations
por: Miravitlles, Marc, et al.
Publicado: (2017)

When is dual bronchodilation indicated in COPD?
por: Thomas, Mike, et al.
Publicado: (2017)

Three-minute constant rate step test for detecting exertional dyspnea relief after bronchodilation in COPD
por: Borel, Benoit, et al.
Publicado: (2016)

Effects of the salbutamol bronchodilator response on measurements of fractional exhaled nitric oxide in children with asthma: a prospective, observational study
por: Wu, Pei-Qiong, et al.
Publicado: (2022)

Dual bronchodilation with tiotropium/olodaterol further reduces activity-related breathlessness versus tiotropium alone in COPD
por: Maltais, François, et al.
Publicado: (2019)

Stereomicroscopic Evaluation of Marginal Fit of E.Max Press and E.Max Computer-Aided Design and Computer-Assisted Manufacturing Lithium Disilicate Ceramic Crowns: An In vitro Study
por: Elrashid, Afra Hassan, et al.
Publicado: (2019)

Impact of bronchodilator therapy on exercise tolerance in COPD
por: Aguilaniu, B
Publicado: (2010)

The role of bronchodilator treatment in the prevention of exacerbations of COPD
por: Wedzicha, Jadwiga A., et al.
Publicado: (2012)

Flow and volume response to bronchodilator in patients with COPD
por: Matteo, Vigna, et al.
Publicado: (2018)

Measuring disease activity in COPD: is clinically important deterioration the answer?
por: Singh, Dave, et al.
Publicado: (2020)

Correction to: Measuring disease activity in COPD: is clinically important deterioration the answer?
por: Singh, Dave, et al.
Publicado: (2021)

Patient-reported outcomes of dual bronchodilator fixed-dose combination versus bronchodilator monotherapy in individuals with COPD
por: Strange, Charlie, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0qoqemp5t71lhcbvrp8qqfv5ek